111 Capital Purchases Shares of 1,154 Stryker Co. (NYSE:SYK)

111 Capital acquired a new position in shares of Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,154 shares of the medical technology company's stock, valued at approximately $415,000.

Several other hedge funds have also recently bought and sold shares of the stock. NorthCrest Asset Manangement LLC raised its holdings in Stryker by 0.7% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 49,884 shares of the medical technology company's stock worth $17,961,000 after purchasing an additional 351 shares during the last quarter. Members Wealth LLC bought a new stake in shares of Stryker during the fourth quarter worth approximately $1,143,000. PKO Investment Management Joint Stock Co acquired a new position in Stryker in the fourth quarter valued at approximately $1,080,000. Centaurus Financial Inc. boosted its stake in Stryker by 16.8% in the fourth quarter. Centaurus Financial Inc. now owns 1,246 shares of the medical technology company's stock valued at $449,000 after acquiring an additional 179 shares during the last quarter. Finally, Wood Tarver Financial Group LLC acquired a new stake in Stryker during the 4th quarter worth $71,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Down 0.7%

SYK stock traded down $2.49 during trading hours on Monday, reaching $380.15. 468,880 shares of the stock were exchanged, compared to its average volume of 1,336,057. The company has a market cap of $145.10 billion, a price-to-earnings ratio of 48.99, a PEG ratio of 2.93 and a beta of 0.93. The firm's 50-day moving average is $368.77 and its 200-day moving average is $376.09. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the company earned $2.50 earnings per share. On average, equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio (DPR) is currently 45.41%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. BTIG Research set a $403.00 price target on Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Needham & Company LLC restated a "buy" rating and set a $442.00 target price on shares of Stryker in a report on Friday, March 21st. JMP Securities restated a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Citigroup reaffirmed a "buy" rating and issued a $455.00 price target (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Finally, Roth Mkm boosted their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $427.30.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.90% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.